The Wayback Machine - https://web.archive.org/all/20050307023816/http://www.med.unc.edu:80/wrkunits/3ctrpgm/alcohol/faculty/FriedM/fried.htm

 

Michael Fried, M.D.

Michael W. Fried , M.D.

Professor of Medicine
Director
Hepatology, Department of Medicine, Division of Gastroenterology and Hepatology

Office | Room 1111 Bioinformatics, CB 7080

Phone | 1.919.966.2516

Email | michael_fried@med.unc.edu

Lab Website | Alcohol Abuse and Hepatitis C


Research Interests

Dr. Fried is studying patients with chronic hepatitis C in order to investigate the effects of alcohol consumption on disease progression. The underlying hypothesis is that alcohol accelerates the rate of liver fibrosis in hepatitis-infected livers through multiple mechanisms that can be individually measured in the laboratory. Studies will determine if chronic alcohol intake enhances the activation of Kupffer cells that increase inflammation of the liver.

Fried is planning a collaboration with David Brenner, M.D., investigator with the Center for Alcohol Studies, and with Bill Renn, director of the Alcohol and Substance Abuse Treatment Program to determine if the progression of liver disease in hepatitis C can be reversed if patients receive counseling and treatment to promote abstinence from alcohol. His studies provide new hope in the treatment of alcohol-related diseases.


News

Dr. Michael W. Fried was recently inducted into the American Society of Clinical Investigation (ASCI) at the organization's annual meeting, April 16-18, 2004, in Chicago, Illinois. The ASCI is an honor society of physician-scientists, those who translate findings in the laboratory to the advancement of clinical practice. Founded in 1908, the Society is home to more than 2,700 members who are in the upper ranks of academic medicine and corporate healthcare.


Center Line Articles


Selected Publications

Click for list of publications from PubMed

Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004 Aug;10(8):1018-23.

Russo MW, Galanko J, Beavers K, Fried MW, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl. 2004 Mar;10(3):340-6.

Fried MW. The NIH roadmap for medical research: bypassing detours. Gastroenterology. 2004 Feb;126(2):392.

Russo MW, Fried MW. Guidelines for stopping therapy in chronic hepatitis C. Curr Gastroenterol Rep. 2004 Feb;6(1):17-21.

Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman SV, Fried MW, Rasenack J, Sarrazin C, Jensen DM, Lin A, Hoffman JH, Sedarati F. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol. 2003 Jul;39(1):106-11.

Ziegler TR, Fernandez-Estivariz C, Gu LH, Fried MW, Leader LM. Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology. 2003 Jun;124(7):1950-7.

Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003 May;124(6):1711-9. Review.

Morgan TR, Brenner D, Everhart J, French SW, Fried MW, Gretch DR, Koziel MJ, McClain CJ, Peters MG, Weinman SA, Lucas DL. Hepatitis C and alcohol: fundamental and translational research directions. Alcohol Clin Exp Res. 2003 Apr;27(4):726-31.

Theodore D, Shiffman ML, Sterling RK, Bruno CJ, Weinstein J, Crippin JS, Garcia G, Wright TL, Conjeevaram H, Reddy RK, Nolte FS, Fried MW. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci. 2003 Jan;48(1):140-5.

Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002 Nov;36(5 Suppl):S237-44.

Jackson EW, Zacks S, Zinn S, Ryan J, Johnson MW, Gerber DA, Andreoni K, Fair JH, Shrestha R, Fried MW. Delayed neuropsychologic dysfunction after liver transplantation for acute liver failure: A matched, case-controlled study. Liver Transpl. 2002 Oct;8(10):932-6.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.

Fried MW. Advances in therapy for chronic hepatitis C. Clin Liver Dis. 2001 Nov;5(4):1009-23. Review.

Zacks SL, Fried MW. Hepatitis B and C and renal failure. Infect Dis Clin North Am. 2001 Sep;15(3):877-99. Review.

Back to Top

 
Bowles Center for Alcohol Studies
University of North Carolina at Chapel Hill
CB#7178, Thurston Bowles Building
Chapel Hill, NC 27599-7178
Tel: (919) 966-5678 • Fax: (919) 966-5679

Updated 01/03/2005  
contact: webmaster 
UNC Home Page 
UNC School of Medicine